# Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)

Source: https://onco.cc/trials/nct06427460/  
OnCo record `nct06427460` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Changhai Hospital, now recruiting.

## Summary

Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) is a phase 2, interventional study registered as NCT06427460 by Changhai Hospital, with a registry enrolment figure of 67 participants, started 2024-05-12 and due to reach its primary completion in 2025-06-30. Interventions recorded: Central-boost ablative dose delivered by stereotactic body radiation therapy. Conditions listed: Pancreatic Cancer. Primary outcome: One-year local control will be determined.. Pancreatic eligibility wording from the registry: "* Pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06427460
- Phase: 2
- Setting: Central-boost Ablative Radiation Therapy for Large Tumors or Tumors Adjacent to Organs at Risk
- Sponsor: Changhai Hospital
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT06427460: https://clinicaltrials.gov/study/NCT06427460

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06427460.json